Prognostic value of CD117 in cancer: A meta-analysis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 1012-1021

  Zhao, Fuyou ^a   Chen, Yuqing ^a   Wu, Qiong ^a   Wang, Zian ^a   Lu, Jie ^a  

^a BENGBU MEDICAL COLLEGE   (China)

Author keywords

CD117; Immunohistochemistry; Meta analysis; Survival

Indexed keywords

STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

BIOSYNTHESIS; CHEMISTRY; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; METABOLISM; MORTALITY; NEOPLASM; PROGNOSIS;

DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 84899563394     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010 CA Cancer J Clin 2010; 60: 277-300.
2. Wang J, Wang B, Chen X and Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcino-genesis 2011; 32: 411-416.
3. Chabot B, Stephenson DA, Chapman VM, Besmer P and Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988 Sep 1; 335: 88-9.
4. Lasota J and Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245-266.
5. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
6. Egger M, Smith GD, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
7. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
8. Rehfeld N, Geddert H, Atamna A, Gabbert HE, Steidl U, Fenk R, Kronenwett R, Haas R and Rohr UP. Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2232-2238.
9. Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum IE and Siegal GP. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Hum Pathol 2010; 41: 1405-1412.
10. Aslan DL, Oprea GM, Jagush SM, Gulbahce HE, Adams GL, Gaffney PM, Savik K and Pambuccian SE. c-kit expression in adenoid cystic carcinoma does not have an impact on local or distant tumor recurrence. Head Neck 2005; 27: 1028-1034.
11. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E and Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 2003; 16: 1035-1040.
12. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL and Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008; 32: 379-382.
13. Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, Berrocal A, Sánchez JJ, Calabuig C and Martorell M. Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications. Lung Cancer 2006; 52: 343-347.
14. Durán I, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, García-Carbonero R, Cortés-Funés H and Paz-Ares L. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol 2010; 12: 443-449.
15. Erdogan G, Bassorgun CI, Pestereli HE, Simsek T, Karaveli S. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS 2007; 115: 204-209.
16. Erler BS, Presby MM, Finch M, Hodges A, Horowitz K, Topilow AA and Matulewicz T. CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumor Biology 2011; 32: 107-111.
17. Fan H, Yuan Y, Wang J, Zhou F, Zhang M, Giercksky KE, Nesland JM and Suo Z. CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome. Histopathology 2013 Jun; 62: 1028-37.
18. Ferrari L, Torre SD, Collini P, Martinetti A, Procopio G, De Dosso S, Bajetta R and Catena L. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 2006; 92: 531.
19. Friederichs J, von Weyhern CW, Rosenberg R, Doll D, Busch R, Lordick F, Siewert JR and Sarbia M. Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. Langenbecks Arch Surg 2010; 395: 373-379.
20. Huang L, Liao LM, Wang HY and Zheng M. Clinicopathologic characteristics and prognostic factors of ovarian fibrosarcoma: the results of a multi-center retrospective study. BMC Cancer 2010; 10: 585.
21. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM and Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010; 117: 248-254.
22. Jones C, Rodriguez-Pinilla M, Lambros M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS and Pritchard-Jones K. c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol 2007; 60: 1226-1231.
23. Kurt E, Sezgin C, Evrensel T, Yalcinkaya U, Kanat O, Veral A, Demiray M, Arslan M, Karabulut B and Ercan I. Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma. Int J Clin Pract 2005; 59: 537-543.
24. Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen N and Butzow R. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004; 91: 2048-2055.
25. Di Lorenzo G, Autorino R, D'Armiento F, Mignogna C, De Laurentiis M, De Sio M, D'Armiento M, Damiano R, Vecchio G and De Placido S. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004; 30: 987-992.
26. de Melo Maia B, Lavorato-Rocha AM, Rodrigues IS, Baiocchi G, Cestari FM, Stiepcich MM, Chinen LT, Carvalho KC, Soares FA and Rocha RM. Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside. J Transl Med 2012; 10: 150.
27. López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, Sánchez-Cespedes M, Castellano D, Bartolomé A and Cortés-Funes H. Prognostic value of KIT expression in small cell lung cancer. Lung Cancer 2007; 56: 405-413.
28. Medinger M, Kleinschmidt M, Mross K, Wehmeyer B, Unger C, Schaefer HE, Weber R and Azemar M. c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis. Pathol Oncol Res 2010; 16: 295-301.
29. Miiji LN, Petrilli AS, Di Cesare S, Odashiro AN, Burnier MN Jr, de Toledo SR, Garcia RJ and Alves MTS. C-kit expression in human osteosarcoma and in vitro assays. Int J Clin Exp Pathol 2011; 4: 775.
30. Murakami A, Mori T, Sakai H, Murakami M, Yanai T, Hoshino Y and Maruo K. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Vet Comp Oncol 2011; 9: 219-224.
31. Pelosi G, Masullo M, Leon ME, Veronesi G, Spaggiari L, Pasini F, Sonzogni A, Iannucci A, Bresaola E and Viale G. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Archiv 2004; 445: 449-455.
32. Petrini I, Zucali PA, Lee HS, Pineda MA, Meltzer PS, Walter-Rodriguez B, Roncalli M, Santoro A, Wang Y and Giaccone G. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010; 5: 1447-1453.
33. Potti A, Moazzam N, Ramar K, Hanekom D, Kargas S and Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003; 14: 894-897.
34. Potti A, Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M and Kargas S. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004; 130: 80-86.
35. Rohr UP, Rehfeld N, Pflugfelder L, Geddert H, Müller W, Steidl U, Fenk R, Gräf T, Schott M and Thiele KP. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004; 111: 259-263.
36. Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S and Crinò L. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 2003; 16: 1041-1047.
37. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert T and Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008; 53: 567-577.
38. Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pasha TL, Salscheider M and Zhang PJ. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int J Gynecol Pathol 2003; 22: 149-155.
39. Sharawat SK, Gupta R, Raina V, Kumar L, Sharma A, Iqbal S, Bakhshi R, Vishnubhatla S and Bakhshi S. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: Independent predictor of poor outcome in pediatric acute myeloid leukemia. Cytometry B Clin Cytom 2013 Nov-Dec; 84: 390-7.
40. Sukpan K, Settakorn J, Khunamornpong S, Cheewakriangkrai C, Srisomboon J and Siriaunkgul S. Expression of survivin, CD117, and C-erbB-2 in neuroendocrine carcinoma of the uterine cervix. Int J Gynecol Cancer 2011; 21: 911-917.
41. Tanaka S, Tanaka H, Yamamoto T, Shuto T, Takemura S, Hai S, Sakabe K, Uenishi T, Hirohashi K and Kubo S. Immunohistochemical demonstration of c-Kit protooncogene product in gallbladder cancer. J Hepatobiliary Pancreat Surg 2006; 13: 228-234.
42. Tonary AM, Macdonald EA, Faught W, Senterman MK and Vanderhyden BC. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 2000; 89: 242-250.
43. Waltari M, Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T and Joensuu H. Association of Merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in Merkel cell carcinoma. Int J Cancer 2011; 129: 619-628.
44. Wei H, Zhao M, Dong W, Yang Y and Li J. Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J Int Med Res 2008; 36: 1008-1014.
45. Winter WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS and Birrer MJ. Clinicopathological analysis of c-kit expression in car cinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003; 91: 3-8.
46. Zhang H, Ye D, Yao X, Dai B, Zhang S, Shen Y, Zhu Y and Mao H. Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients. J Cancer Res Clin Oncol 2009; 135: 249-253.
47. Tay C, Ong C, Lee V and Pang B. KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting. Pathology 2013; 45: 127.
48. Krams M, Parwaresch R, Sipos B, Heidorn K, Harms D and Rudolph P. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 2004; 23: 588-595.
49. Heinrich MC, Blanke CD, Druker BJ and Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-1703.
50. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J and Gewirtz AM. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1996; 4: 176-182.
51. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A and Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-6143.
52. Rygaard K, Nakamura T and Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993; 67: 37.
53. Jacquemier J, Moles J, Penault-Llorca F, Adelaide J, Torrente M, Viens P, Birnbaum D and Theillet C. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846.
54. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C and Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-329.